Most Read Articles
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 5 days ago

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Entecavir comparable to tenofovir for treatment-naïve chronic hepatitis B patients

26 Aug 2019

Entecavir and tenofovir deliver similar prognostic benefits in chronic hepatitis B (CHB) patients naïve to any treatment, a new study has shown.

Researchers enrolled 2,897 CHB patients who were given either entecavir (n=1,484; mean age, 48.2±11.5 years; 59.9 percent male) or tenofovir (n=1,413; mean age, 48.8±12.0 years; 64.6 percent male) as first-line antiviral agents. Patients with hepatocellular carcinoma (HCC) or decompensated cirrhosis were ineligible. Study outcomes included the cumulative probabilities of HCC and death, or the need for orthotopic liver transplant (OLT).

In the overall study population, 240 participants developed HCC, resulting in an incidence rate of 8.3 percent. Analysis according to treatment arms showed that the 1-, 3- and 5-year cumulative HCC risks in the entecavir group were 1.0 percent, 4.8 percent and 9.3 percent, respectively. Corresponding values in the tenofovir group were 1.0 percent, 4.7 percent and 7.7 percent (p=0.517).

Multivariate analysis revealed no significant difference in HCC risk between the two groups (adjusted hazard ratio [HR], 0.975, 95 percent CI, 0.747–1.272; p=0.852).

A similar trend was reported for death and OLT, which was reported in 2.5 percent (n=72) of the entire cohort. The respective cumulative risk rates at 1, 3 and 5 years were 0.5 percent, 1.8 percent and 2.6 percent in the entecavir group, and 0.2 percent, 1.4 percent and 2.5 percent in the tenofovir group (p=0.981).

The likelihood of death or OLT was likewise comparable between treatment arms (adjusted HR, 1.202, 0.745–1.939; p=0.451).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 5 days ago

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates.